AKTX CIK: 1541157

Akari Therapeutics Plc

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−18.8
FY22:
−21.5
FY23:
−16.4
FY24:
−12.6
FY25:
−10.6
millions USD
FY21:
–
FY22:
–
FY23:
–
FY24:
0.38
FY25:
–
Change from FY21 to FY25
millions USD
FY21:
14.3
FY22:
25.3
FY23:
7.02
FY24:
11.0
FY25:
13.2
millions USD
FY21:
−4.69
FY22:
3.89
FY23:
−9.41
FY24:
−1.19
FY25:
2.60

All amounts in millions USD Data source:SEC EDGAR